Based on the earnings transcript for Merck & Co., Inc., the company reported strong first-quarter results with double-digit EPS growth and sales growth. Management highlighted the company's ability to grow both the top line and the bottom line, driven by key products such as JANUVIA, JANUMET, SINGULAIR, REMICADE, ISENTRESS, and NASONEX. The company also reported progress in its late-stage pipeline, with multiple approvals and new product launches expected in 2011. Additionally, the company announced a $5 billion stock buyback program, demonstrating its commitment to returning cash to shareholders.

The short-term implications for Merck & Co., Inc. are positive. The company's strong performance and growth prospects are likely to be well-received by investors, leading to a potential stock price increase. However, the stock may face temporary pressure due to the uncertainty surrounding the J&J arbitration settlement and the potential impact on earnings in the second half of the year.

Overall, the short-term impact on the stock price of Merck & Co., Inc. is likely to be positive, driven by the company's strong first-quarter results, growth prospects, and commitment to returning cash to shareholders.

Rating: 1